These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34349063)

  • 1. [Update on factor (F) VIII structure and function-related hemostatic coagulation and its regulatory mechanism (s)].
    Nogami K
    Rinsho Ketsueki; 2021; 62(7):781-789. PubMed ID: 34349063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab.
    Yada K; Nogami K
    Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1148-1154. PubMed ID: 32237902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
    Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clot waveform analysis for perioperative hemostatic monitoring in a hemophilia A patient on emicizumab undergoing liver transplantation.
    Awane M; Wakui M; Ozaki Y; Kondo Y; Oka S; Fujimori Y; Yatabe Y; Arai T; Yamada Y; Hori S; Obara H; Hasegawa Y; Matsushita H
    Clin Chim Acta; 2023 Apr; 544():117339. PubMed ID: 37076096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence.
    Leksa NC; Aleman MM; Goodman AG; Rabinovich D; Peters R; Salas J
    J Thromb Haemost; 2019 Jul; 17(7):1044-1052. PubMed ID: 30887655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
    Girard TJ; Lasky NM; Grunz K; Broze GJ
    J Thromb Haemost; 2019 Jan; 17(1):149-156. PubMed ID: 30451376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
    Yada K; Nogami K; Shinozawa K; Kitazawa T; Hattori K; Amano K; Fukutake K; Shima M
    Br J Haematol; 2018 Oct; 183(2):257-266. PubMed ID: 30125997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
    Baumgartner CK; Mattson JG; Weiler H; Shi Q; Montgomery RR
    J Thromb Haemost; 2017 Jan; 15(1):98-109. PubMed ID: 27496751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays.
    Radtke KP; Griffin JH; Riceberg J; Gale AJ
    J Thromb Haemost; 2007 Jan; 5(1):102-8. PubMed ID: 17059431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.
    Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
    Thromb Haemost; 2021 Mar; 121(3):279-286. PubMed ID: 32906155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions.
    Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
    Thromb Res; 2021 Feb; 198():7-16. PubMed ID: 33248318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex.
    Kamikubo Y; Mendolicchio GL; Zampolli A; Marchese P; Rothmeier AS; Orje JN; Gale AJ; Krishnaswamy S; Gruber A; Østergaard H; Petersen LC; Ruf W; Ruggeri ZM
    Blood; 2017 Oct; 130(14):1661-1670. PubMed ID: 28729433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High levels of factor VIII activity in patients with acquired hemophilia A in remission are associated with unusually low coagulation potentials.
    Shibasaki F; Takeyama M; Ogiwara K; Furukawa S; Nakajima Y; Shimonishi N; Nogami K
    Int J Hematol; 2023 May; 117(5):669-677. PubMed ID: 36607560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.
    Díaz-Ricart M; Isola IM; Escolar G
    Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A.
    Müller J; Pekrul I; Pötzsch B; Berning B; Oldenburg J; Spannagl M
    Thromb Haemost; 2019 Sep; 119(9):1384-1393. PubMed ID: 31203578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential.
    Nakajima Y; Takeyama M; Oda A; Shimonishi N; Nogami K
    Blood Adv; 2023 Apr; 7(8):1436-1445. PubMed ID: 36322904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma.
    Yada K; Ogiwara K; Shimonishi N; Nakajima Y; Soeda T; Kitazawa T; Nogami K
    Int J Hematol; 2024 Feb; 119(2):109-118. PubMed ID: 38112996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma.
    Strijbis VJF; Romano LGR; Cheung KL; Eikenboom J; Liu YP; McCreary AC; Leebeek FWG; Bos MHA
    J Thromb Haemost; 2023 Jun; 21(6):1466-1477. PubMed ID: 36863564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.
    Adamkewicz JI; Chen DC; Paz-Priel I
    Thromb Haemost; 2019 Jul; 119(7):1084-1093. PubMed ID: 31064025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
    Lenting PJ; Denis CV; Christophe OD
    Blood; 2017 Dec; 130(23):2463-2468. PubMed ID: 29042366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.